Pediatrics Guillain-Barré Syndrome: A case series
DOI:
https://doi.org/10.33448/rsd-v12i13.44236Keywords:
Guillain-Barre Syndrome; Pediatrics; Brazil; Human intravenous immunoglobulins.Abstract
This research aimed to evaluate clinical and epidemiological features of patients aged 1 to 13 years, diagnosed with Guillain-Barre Syndrome (GBS) in a Universitary Hospital between January 2019 and June 2023. It was performed a retrospective, descriptive analysis of medical records. There were 5 cases recorded with the usual manifestation of GBS, progressive ascending paralysis with diminished reflexes, with varying evolution time. Only two cases had associated diminished sensibility. Four cases had their cerebrospinal fluid analyzed, which was useful in confirming the diagnosis. An electroneuromyography study was performed in the 5 cases, with only one case of the demyelinating form of GBS and the other four cases being the motor axonal form. Through the analysis of clinical history, previous infectious symptoms, serological and viremia tests, it was possible to presume an etiology in two cases, being previous COVID-19 and Gastroenteritis. One case had a temporal correlation with the Poliomyelitis Oral Vaccine and anti-Yellow Fever vaccine. They were all treated with Human Immunoglobulin in order to reduce the recovery time, with a positive effect in three cases. One of the other cases had a cardiorespiratory arrest in the fourth day of Immunoglobulin administration and the other case didn’t show any response with the first dose, so the dose was repeated, when the patient finally presented a positive response. In conclusion, cases of GBS have varying time evolution and level of severity, so it’s necessary to recognise the symptoms and diagnosis fastly, in order to start the treatment, preventing greater disability.
References
Alessandro, L., Castiglione, J. I., Brand, P., Bruno, V., & Barroso, F. (2022). Treatment-related fluctuations in Guillain-Barré syndrome: clinical features and predictors of recurrence. Arquivos de neuro-psiquiatria, 80(5), 516–522.
Arsenijević, M., Berisavac, I., Mladenović, B., Stanarčević, P., Jovanović, D., Lavrnić, D., & Peric, S. (2021). Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease. Irish journal of medical science, 190(1), 357–361.
Assis, L. C., Souza, T. I. M., Aninger, G. T., & Moura, A. S. (2020). Testes sorológicos no diagnóstico da Covid-19: Revisão de literatura. Revista Conexão Ciência; 15(4), 59-69.
Carneiro-Sampaio, M.; Sumita, N. M.; Slhessarenko, N.; Duarte, A. J. S. (2022). Medicina Laboratorial em Pediatria. Ed. Manole.
Cecatto, S. B., Garcia, R. I. D., Costa, K. S., Novais, R. A. B., Yoshimura, R., & Rapoport, P. B. (2003). Síndrome de Guillain-Barré como complicação de amigdalite aguda. Revista Brasileira De Otorrinolaringologia, 69(4), 566–569.
Chen, Y., Zhang, J., Chu, X., Xu, Y., & Ma, F. (2020). Vaccines and the risk of Guillain-Barré syndrome. European journal of epidemiology, 35(4), 363–370.
Costa, R. E. A. R., Sousa, J. P. de, Pereira, P. E. C., Figueira, P. H. A., Linhares, N. dos S., Vanti, T. R. N., Macedo, J. L., Almeida, F. A. F. L., Raiol, S. R. do N., Rodrigues, K. S., Pamplona, R. B., Araújo, F. W. C., Mendes, A. M., Alves, D. R. C. F., Brandão, M. C. B., & Ferreira, M. B. (2020). Guillain-Barré syndrome associated with viral infections. Research, Society and Development, 9(8), e904986195.
de Montaudouin, M., Fleury, O., Rouanet, M., Renou, P., Rouanet, F., & Sibon, I. (2014). Hyperacute Guillain-Barré syndrome mimicking stroke: report of 3 cases: Guillain-Barré and stroke. The American journal of emergency medicine, 32(9), 1152.e3-1152.e5.
Dias-Tosta, E. & Kückelhaus, C. S. (2002). Guillain Barré syndrome in a population less than 15 years old in Brazil. Arquivos de Neuro-Psiquiatria, 60(2B), 367–373.
Dourado, M. E., Freitas, M. L. D., & Santos, F. M. D. (1998). Síndrome de Guillain-Barré com flutuações relacionadas ao tratamento com imunoglobulina humana endovenosa (curso trifásico): relato de caso. Arquivos De Neuro-psiquiatria, 56(3A), 476–479.
Dourado-Junior, M. E. T., Sousa, B. F. de., Costa, N. M. C. da., & Jeronimo, S. M. B.. (2021). Cytomegalovirus infection in Guillain-Barré syndrome: a retrospective study in Brazil. Arquivos De Neuro-psiquiatria, 79(7), 607–611.
Finsterer, J., Matovu, D., & Scorza, F. A. (2022). SARS-CoV-2 vaccinations reduce the prevalence of post-COVID Guillain-Barre syndrome. Clinics (Sao Paulo, Brazil), 77, 100064.
Goodfellow, J. A., & Willison, H. J. (2016). Guillain-Barré syndrome: a century of progress. Nature reviews. Neurology, 12(12), 723–731.
Khedr, E. M., Shehab, M. M., Mohamed, M. Z., & Mohamed, K. O. (2023). Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome. Scientific reports, 13(1), 14000.
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A., Bateman, K., Ferreira, M. L., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A., Islam, B., Kusunoki, S., Pardo, C. A., Reisin, R., Sejvar, J. J., Shahrizaila, N., Soares, C., Umapathi, T., Wang, Y., Yiu, E. M., Willison, H. J., & Jacobs, B. C. (2021). Diretrizes Baseadas em Evidências Diagnóstico e manejo da Síndrome de Guillain–Barré em dez etapas. Revista Neurociências, 29, 1–52.
Ministério da Saúde. (2011). Manual técnico de diagnóstico laboratorial de Campylobacter: gênero Campylobacter: diagnóstico laboratorial clássico e molecular. Brasília, Distrito Federal, Brasil. <https://bvsms.saude.gov.br/bvs/publicacoes/manual_tecnico_diagnostico_laboratorial_campylobacter.pdf> Acesso em: 18 out. 2023.
Nachamkin, I., Arzarte Barbosa, P., Ung, H., Lobato, C., Gonzalez Rivera, A., Rodriguez, P., Garcia Briseno, A., Cordero, L. M., Garcia Perea, L., Perez, J. C., Ribera, M., Aldama, P. C., Guitérrez, G. D., Sarnat, L. F., García, M. R., Veitch, J., Fitzgerald, C., Cornblath, D. R., Rodriguez Pinto, M., Griffin, J. W., Willison, H. J., & McKhann, G. M. (2007). Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology, 69(17), 1665–1671.
Neumeister, J., Huang, D., Dzluneski, S., Huttleston, A. M., Megargel, C., Falgiani, M., & Ganti, L. (2023). Hyperacute and Fulminant Guillain-Barré Syndrome Requiring Emergent Intubation. Cureus, 15(5), e38499.
Oliveira, D. R. da C. A. B., Fernandez, R. N. M., Grippe, T. C., Baião, F. S., Duarte, R. L., & Fernandez, D. J. (2021). Epidemiological and clinical aspects of Guillain-Barré syndrome and its variants. Arquivos De Neuro-psiquiatria, 79(6), 497–503.
Sejvar, J. J., Baughman, A. L., Wise, M., & Morgan, O. W. (2011). Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology, 36(2), 123–133.
Shahrizaila, N., Lehmann, H. C., & Kuwabara, S. (2021). Guillain-Barré syndrome. Lancet (London, England), 397(10280), 1214–1228.
Torres-Duque, C.A., Patino, C.M. & Ferreira, J.C. (2020). Série de casos: delineamento de estudo essencial para a construção de conhecimento e a proposição de hipóteses para doenças raras e novas. Jornal Brasileiro de Pneumologia, 46(4), e20200389.
Willison, H. J., Jacobs, B. C., & van Doorn, P. A. (2016). Guillain-Barré syndrome. Lancet (London, England), 388(10045), 717–727.
Yuki, N., & Hirata, K. (1998). Fisher's syndrome and group A streptococcal infection. Journal of the neurological sciences, 160(1), 64–66.
Zaki, H. A., Iftikhar, H., Najam, M., Masood, M., Al-Marri, N. D. R., Elgassim, M. A. M., Fayed, M., & Shaban, E. E. (2023). Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis. eNeurologicalSci, 31, 100468.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Lúcia Delphino Rodrigues; Valeriane Maia Siravegna Benavides
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
